## **Core Concept**
Rofecoxib is a **coxib**, a class of **nonsteroidal anti-inflammatory drugs (NSAIDs)** that specifically inhibit **cyclooxygenase-2 (COX-2)**, an enzyme involved in inflammation and pain. COX-2 inhibitors were developed to reduce gastrointestinal side effects associated with traditional NSAIDs.

## **Why the Correct Answer is Right**
The correct answer, , indicates that Rofecoxib was withdrawn due to concerns over **increased risk of cardiovascular events**, such as heart attacks and strokes. This was attributed to the imbalance in **thromboxane A2** (produced by COX-1) and **prostacyclin** (produced by COX-2) levels, favoring vasoconstriction and platelet aggregation. The **Adenomatous Polyposis Coli (APC) trial** provided evidence that led to its withdrawal.

## **Why Each Wrong Option is Incorrect**
* **Option A:** - This option is incorrect because, although gastrointestinal side effects are a concern with NSAIDs, Rofecoxib was specifically designed to reduce these side effects by targeting COX-2.
* **Option B:** - This option is incorrect as there is no established link between Rofecoxib and hepatotoxicity leading to its withdrawal.
* **Option C:** - This option is incorrect because, while nephrotoxicity is a concern with NSAIDs, it was not the primary reason for Rofecoxib's withdrawal.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **COX-2 inhibitors** like Rofecoxib were withdrawn or restricted due to **cardiovascular risks**. This highlights the importance of considering cardiovascular safety when prescribing NSAIDs.

## **Correct Answer Line**
**Correct Answer: D. Increased risk of cardiovascular events.**